Current translational and clinical practices in hematopoietic cell and gene therapy

Cytotherapy

Volumn 14, Issue 7, 2012, Pages 775-790

  Digiusto, David L ^a   Kiem, Hans Peter ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adoptive immunotherapy; Cell therapy; Clinical trials; Gene therapy; Stem cells

Indexed keywords

CYCLOPHOSPHAMIDE; DNA BINDING PROTEIN; FLUDARABINE; INTERLEUKIN 2; IPILIMUMAB; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE; ZINC FINGER NUCLEASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; BIOREACTOR; CANCER GENE THERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL ENGINEERING; CELL EXPANSION; CELL SELECTION; CELL SORTER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DNA MODIFICATION; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOREACTIVITY; LYMPHOID CELL LINE; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL GENE THERAPY; T LYMPHOCYTE; TRANSLATIONAL RESEARCH; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84863930204     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.694420     Document Type: Review

References (194)

1. Drolet BC, Lorenzi NM. Translational research: Understanding the continuum from bench to bedside. Translation Res J Lab Clin Med. 2011;157:1-5.
2. Zerhouni EA. Clinical research at a crossroads: The NIH roadmap. J Invest Med. 2006;54:171-3.
3. Westfall JM, Mold J, Fagnan L. Practice-Based research: ' Blue Highways ' on the NIH roadmap. J Am Med Assoc. 2007;297:403-6.
4. Silvestri F, Banavali S, Baccarani M, Preisler HD. The CD34 hemopoietic progenitor cell associated antigen: Biology and clinical applications. Haematologica. 1992;77:265-73.
5. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that infl uence collection and engraftment of autologous peripheral-Blood stem cells. J Clin Oncol. 1995;13:2547-55.
6. Naldini L. Ex vivo gene transfer and correction for cell-Based therapies. Nat Rev Genet. 2011;12:301-15.
7. Riviere I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood. 2012;119:1107-16.
8. Butturini A, Bortin MM, Gale RP. Graft-Versus-Leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2:233-42.
9. Zaia JA. Prevention and management of CMV-Related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:633-8.
10. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999;11:96-101.
11. Howard DS, Phillips IG, Reece DE, Munn RK, Henslee- Downey J, Pittard M, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29:1494-501.
12. Greenberg P, Goodrich J, Riddell S. Adoptive immunotherapy of human cytomegalovirus infection: Potential role in protection from disease progression. Transplant Proc. 1991;23:97-101.
13. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodefi cient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-41.
14. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-Cell clones from the donor. N Engl J Med. 1995;333:1038-44.
15. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al. Long-Term restoration of immunity against Epstein -Barr virus infection by adoptive transfer of gene-Modified virus-Specifi c T lymphocytes. Nat Med. 1996;2:551-5.
16. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-Associated malignancies. Blood. 2003;101: 1905-12.
17. Leen AM, Sili U, Savoldo B, Jewell AM, Piedra PA, Brenner MK, et al. Fiber-Modified adenoviruses generate subgroup 32. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26: 5233-9.
18. O' R eilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-Specifi c T-Cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007;38:237-50.
19. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7:1159-62.
20. Chatziandreou I, Gilmour KC, McNicol AM, Costabile M, Sinclair J, Cubitt D, et al. Capture and generation of adenovirus specifi c T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117-26.
21. Kerns HM, Ryu BY, Stirling BV, Sather BD, Astrakhan A, Humblet-Baron S, et al. B cell-Specifi c lentiviral gene therapy leads to sustained B-Cell functional recovery in a murine model of X-Linked agammaglobulinemia. Blood. 2010;115: 2146-55.
22. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-Derived T lymphocytes specifi c for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12: 1160-6.
23. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114:4283-92.
24. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specifi city after stem cell transplantation. Cytotherapy. 2011;13:976-86.
25. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-Term outcome of EBV-Specifi c T-Cell infusions to prevent or treat EBV-Related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-35.
26. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-Cell transplantation with virus-Specifi c T-Cell lines. Lancet. 2003;362:1375-7.
27. + ) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specifi c adoptive immunotherapy. Cytotherapy. 2010;12:933-44.
28. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, et al. Adverse events following infusion of T cells for adoptive immunotherapy: A 10-Year experience. Cytotherapy. 2010; 12:743-9.
29. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, et a l. Production of good manufacturing practice-grade cytotoxic T lymphocytes specifi c for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections postallogeneic hematopoietic stem cell transplant. Cytotherapy. 2012;14:7-11.
30. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumorinfi ltrating lymphocytes Modified by retroviral gene transduction. N Engl J Med. 1990;323:570-8.
31. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-Infi ltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-42.
32. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-40.
33. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-Cell transfer immunotherapy. Clin Cancer Res. 2011; 17:4550-7.
34. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-45.
35. + T cells. J Exp Med. 2005; 202:907-12.
36. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22: 223-30.
37. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-Specifi c CD8 T cells in metastases from melanoma patients. J Clin Invest. 2011;121:2350-60.
38. Ohta T, Kikuchi H, Ogata H, Iwata K, Yoshida K, Katayama K, et al. Effect of anti-CD3 antibody on the generation of interleukin-2-Activated lymphocytes from tumor tissues of gastrointestinal cancer. Cancer. 1992;70:741-8.
39. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specifi c cytolysis by tumor infi ltrating lymphocytes in breast cancer. Cancer. 1994;74:1275-82.
40. Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, et al. Restoration of tumor-Specifi c HLA class I restricted cytotoxicity in tumor infi ltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-Pulsed autologous dendritic cells. Breast Cancer Res Treat. 2003;80:275-85.
41. Santin AD, Bellone S, Palmieri M, Bossini B, Cane S, Bignotti E, et al. Restoration of tumor specifi c human leukocyte antigen class I-Restricted cytotoxicity by dendritic cell stimulation of tumor infi ltrating lymphocytes in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2004; 14:64-75.
42. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg. 2011;45:341-60.
43. Semino C, Martini L, Queirolo P, Cangemi G, Costa R, Alloisio A, et al. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience. Anticancer Res. 1999;19:5645-9.
44. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107:1325-31.
45. R apoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, et al. Combination immunotherapy using adoptive T-Cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117:788-97.
46. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-Reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol. 1999;163:507-13
47. Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, Kato I, et al. Functional reconstitution of class II MHC-Restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol. 2000;165:528-32.
48. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specifi city for human immunodefi ciency virus type 1 into primary human T lymphocytes by introduction of T-Cell receptor genes. J Virol. 2000;74:8207-12.
49. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modifi cation to redirect effector cell specifi city. Cancer J. 2010;16:336-41.
50. Eshhar Z, Waks T, Gross G, Schindler DG. Specifi c activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-Binding domains and the gamma or zeta subunits of the immunoglobulin and T-Cell receptors. Proc Natl Acad Sci USA. 1993;90:720-4.
51. McKeever U, Khandekar S, Newcomb J, Naylor J, Gregory P, Brauer P, et al. Immunization with soluble BDC 2.5 T cell receptor-Immunoglobulin chimeric protein: Antibody specifi city and protection of nonobese diabetic mice against adoptive transfer of diabetes by maternal immunization. J Exp Med. 1996;184:1755-68.
52. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666-8.
53. Peinert S, Kershaw MH, Prince HM. Chimeric T cells for adoptive immunotherapy of cancer: Using what have we learned to plan for the future. Immunotherapy. 2009;1: 905-12.
54. Levine BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther. 2008;8:475-89.
55. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-Directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825-33.
56. K ohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, et al. CARs on track in the clinic. Mol Ther. 2011;19:432-8.
57. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-Specifi c immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-Modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107:2294-302.
58. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-Specifi c chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245-56.
59. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-Infi ltrating lymphocytes from activation-Induced cell death and enhances antitumor effector function. J Immunother. 2011;34:236-50.
60. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefi ts from combined CD28-OX40 signalling. Int J Cancer. 2011;129:2935-44.
61. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-Specifi c chimeric antigen receptor enhances in vivo persistence and antitumor effi cacy of adoptively transferred T cells. Cancer Res. 2006;66:10995-1004.
62. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic effi cacy in vivo. Mol Ther. 2009;17:1453-64.
63. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011; 71:4617-27.
64. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, et al. Development and application of CD19-Specifi c T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis. 2004;33:83-9.
65. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32:689-702.
66. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116: 3875-86.
67. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-Specifi c T cells with IL-21 signaling can improve adoptive immunotherapy of B-Lineage malignancies. Cancer Res. 2011;71:3516-27.
68. + T cells derived from virus-Specifi c central memory T cells. Blood. 2012;119:72-82.
69. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32:169-80.
70. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-Cell leukemias. Blood. 2011;118:4817-28.
71. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-Modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-33.
72. + T cells. J Clin Invest. 2005; 115:1616-26.
73. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106:17469-74.
74. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117:808-14.
75. Lan KL, Ou-Yang F, Yen SH, Shih HL, Lan KH. Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer. Clin Exp Metastasis. 2010;27: 307-18.
76. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
77. + T cells survives cytotoxic chemotherapy. Immunity. 2009;31: 834-44.
78. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-Term survival for primary immunodefi ciencies in Europe: Entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602-10.
79. Szabolcs P, Cavazzana-Calvo M, Fischer A, Veys P. Bone marrow transplantation for primary immunodefi ciency diseases. Pediatr Clin North Am. 2010;57:207-37.
80. Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: Scientific basis, current status and future directions. Br J Haematol. 2010;148:356-72.
81. Hutter G, Zaia JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodefi ciency virus: The experiences of more than 25 years. Clin Exp Immunol. 2011;163:284-95.
82. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-Immunodefi cient patients. Science. 1995;270:470-5.
83. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-3.
84. + cells in ADAdefi cient SCID neonates. Nat Med. 1998;4:775-80.
85. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodefi ciency due to adenosine deaminase defi ciency. N Engl J Med. 2009;360:447-58.
86. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219-34.
87. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-Mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132-42.
88. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143-50.
89. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, et al. Long-Term persistence of a polyclonal T cell repertoire after gene therapy for X-Linked severe combined immunodefi ciency. Sci Transl Med. 2011;3:97ra79.
90. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, et al. Failure of SCID-X1 gene therapy in older patients. Blood. 2005;105:4255-7.
91. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA, et al. Stem-Cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363: 1918-27.
92. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198-204.
93. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-Linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12:401-9.
94. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-Long safety and function of retroviral-Modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53.
95. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-Linked adrenoleukodystrophy. Science. 2009;326:818-23.
96. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial refl ect a benign integration bias and not oncogenic selection. Blood. 2011;117: 5332-9.
97. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-Thalassaemia. Nature. 2010;467:318-22.
98. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-Associated virus vector-Mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357-65.
99. Roy K, Stein L, Kaushal S. Ocular gene therapy: An evaluation of recombinant adeno-Associated virus-Mediated gene therapy interventions for the treatment of ocular disease. Hum Gene Ther. 2010;21:915-27.
100. + ) cells in patients undergoing transplantation for AIDS-Related lymphoma. Sci Transl Med. 2010; 36ra43.
101. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, et al. Durable remissions with autologous stem cell transplantation for high-Risk HIV-Associated lymphomas. Blood. 2005;105:874-8.
102. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, et al. Human hematopoietic stem/progenitor cells Modified by zinc-Finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28:839-47.
103. + )cells. Mol Ther. 2005;12:77-86.
104. Zinno F, Landi F, Scerpa MC, Aureli V, Lanti A, Ceccarelli S, et al. Processing of hematopoietic stem cells from peripheral blood before cryopreservation: Use of a closed automated system. Transfusion. 2011;51:2656-63.
105. Janssen WE, Ribickas A, Meyer LV, Smilee RC. Large-Scale Ficoll gradient separations using a commercially available, effectively closed, system. Cytotherapy. 2010;12:418-24.
106. Aktas M, Radke TF, Strauer BE, Wernet P, Kogler G. Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. Cytotherapy. 2008;10:203-11.
107. Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-Scale enrichment of lymphocytes for use in adoptive immunotherapy using a Modified counterflow centrifugal elutriation program. Cytotherapy. 2009;11: 923-35.
108. Perseghin P, D 'A mico G, Dander E, Gaipa G, Dassi M, Biagi E, et al. Isolation of monocytes from leukapheretic products for large-Scale GMP-grade generation of cytomegalovirus-Specifi c T-Cell lines by means of an automated elutriation device. Transfusion. 2008;48:1644-9.
109. Kim S, Kim HO, Baek EJ, Choi Y, Kim HS, Lee MG. Monocyte enrichment from leukapheresis products by using the Elutra cell separator. Transfusion. 2007;47:2290-6.
110. Gonzalez-Vicent M, Perez A, Abad L, Sevilla J, Ramirez M, Diaz MA. Graft manipulation and reduced-Intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/ haploidentical related donors in pediatric leukemia patients. J Pediatr Hematol Oncol. 2010;32:85-90.
111. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, et al. Low risk of chronic graft-Versus-host disease and relapse associated with T cell-Depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in First remission: Results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011;17:1343-51.
112. + cells from melanoma tumor-Infi ltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother. 2010;33: 547-56.
113. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-Specifi c T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360-7.
114. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, et al. Vaccination with autologous tumor-Loaded dendritic cells induces clinical and immunologic responses in indolent B-Cell lymphoma patients with relapsed and measurable disease: A pilot study. Blood. 2009;113:18-27.
115. Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, et al. Costimulated tumor-Infi ltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 2012;119:2956-2959.
116. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profi le and detection kinetics. Blood. 2011;117:1061-70.
117. Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, et al. Rapid immune recovery and graft-Versushost disease-Like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009;15:4499-507.
118. + ) T cells to HIV-Infected persons. Clin Immunol. 2004;111: 262-74.
119. Orchard PJ, Blazar BR, Burger S, Levine B, Basso L, Nelson DM, et al. Clinical-Scale selection of anti-CD3/ CD28-Activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther. 2002;13:979-88.
120. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-Term multilineage engraftment. Science. 2011;333: 218-21.
121. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571-6.
122. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-Like properties. Nat Med. 2011;17:1290-7.
123. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-System culture process. PLoS One. 2011;6:e20740.
124. Sensebe L. Clinical grade production of mesenchymal stem cells. Biomed Mater Eng. 2008;18:S3-10.
125. Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ, et al. Manufacturing of large numbers of patientspecifi c T cells for adoptive immunotherapy: An approach to improving product safety, composition, and production capacity. J Immunother. 2007;30:644-54.
126. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-Specifi c T cells for preclinical and clinical applications using gas-Permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33:305-15.
127. Sadeghi A, Pauler L, Anneren C, Friberg A, Brandhorst D, Korsgren O, et al. Large-Scale bioreactor expansion of tumor-Infi ltrating lymphocytes. J Immunol Methods. 2011; 364:94-100.
128. Hami LS, Green C, Leshinsky N, Markham E, Miller K, Craig S. GMP production and testing of Xcellerated T cells for the treatment of patients with CLL. Cytotherapy. 2004;6:554-62.
129. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-Mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16:232-6.
130. + cord blood cells through the activation of Jak-PI3K-STAT3 pathway. Am J Pathol. 2012;180: 351-64.
131. Auvray C, Delahaye A, Pfl umio F, Haddad R, Amsellem S, Miri-Nezhad A, et al. HOXC4 homeoprotein Efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4. Haematologica. 2012;97: 168-78.
132. Watts KL, Nelson V, Wood BL, Trobridge GD, Beard BC, Humphries RK, et al. Hematopoietic stem cell expansion facilitates multilineage engraftment in a nonhuman primate cord blood transplantation model. Exp Hematol. 2011;40: 187-196.
133. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329:1345-8.
134. Horn PA, Thomasson BM, Wood BL, Andrews RG, Morris JC, Kiem HP. Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. Blood. 2003;102: 4329-35.
135. Mezquita P, Beard BC, Kiem HP. NOD/SCID repopulating cells contribute only to short-Term repopulation in the baboon. Gene Ther. 2008;15:1460-2.
136. Kohn DB. Lentiviral vectors ready for prime-Time. Nat Biotechnol. 2007;25:65-6.
137. Papanikolaou E, Anagnou NP. Major challenges for gene therapy of thalassemia and sickle cell disease. Curr Gene Ther. 2010;10:404-12.
138. Dropulic B. Lentiviral vectors: Their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther. 2011;22:649-57.
139. Klages N, Zufferey R, Trono D. A stable system for the hightiter production of multiply attenuated lentiviral vectors. Mol Ther. 2000;2:170-6.
140. Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther. 2001;12:981-97
141. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-Titer self-Inactivating lentiviral vectors. Mol Ther. 2001;3:97-104.
142. Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, et al. Generation of a packaging cell line for prolonged largescale production of high-Titer HIV-1-Based lentiviral vector. J Gene Med. 2005;7:818-34.
143. Witting SR, Li LH, Jasti A, Allen C, Cornetta K, Brady J, et al. Efficient large volume lentiviral vector production using flow electroporation. Hum Gene Ther. Volume 23(2): 243-9.
144. Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. An inducible packaging cell system for safe, Efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology. 2001;282:77-86.
145. Broussau S, Jabbour N, Lachapelle G, Durocher Y, Tom R, Transfi guracion J, et al. Inducible packaging cells for largescale production of lentiviral vectors in serum-Free suspension culture. Mol Ther. 2008;16:500-7.
146. Stewart HJ, Leroux-Carlucci MA, Sion CJ, Mitrophanous KA, Radcliffe PA. Development of inducible EIAV-Based lentiviral vector packaging and producer cell lines. Gene Ther. 2009;16:805-14.
147. Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C, et al. Large-Scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther. 2011;22:343-56.
148. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc Finger nucleases and
149. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, et al. Enhancing zinc-Finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 2011;8:74-9.
150. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, et al. An improved zinc-Finger nuclease architecture for highly specifi c genome editing. Nat Biotechnol. 2007;25: 778-85.
151. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al. Highly Efficient endogenous human gene correction using designed zinc-Finger nucleases. Nature. 2005;435:646-51.
152. Carroll D, Morton JJ, Beumer KJ, Segal DJ. Design, construction and in vitro testing of zinc Finger nucleases. Nat Protoc. 2006;1:1329-41.
153. Porteus MH. Mammalian gene targeting with designed zinc Finger nucleases. Mol Ther. 2006;13:438-46.
154. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc Finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA. 1996;93:1156-60.
155. Cannon P, June C. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS. 2011;6:74-9.
156. + T cells with CXCR4-Specifi c zinc-Finger nucleases. PLoS Pathog. 2011;7: E1002020.
157. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc Finger nucleases. Stem Cells. 2011;29: 1717-26.
158. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475:217-21.
159. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, et al. Targeted gene correction of alpha1-Antitrypsin defi ciency in induced pluripotent stem cells. Nature. 2011;478:391-4.
160. Ramalingam S, Kandavelou K, Rajenderan R, Chandrasegaran S. Creating designed zinc-Finger nucleases with minimal cytotoxicity. J Mol Biol. 2011;405:630-41.
161. Cornu TI, Cathomen T. Quantifi cation of zinc Finger nucleaseassociated toxicity. Methods Mol Biol. 2010;649:237-45.
162. Pruett-Miller SM, Reading DW, Porter SN, Porteus MH. Attenuation of zinc Finger nuclease toxicity by small-Molecule regulation of protein levels. PLoS Genet. 2009;5:e1000376.
163. Pattanayak V, Ramirez CL, Joung JK, Liu DR. Revealing off-Target cleavage specifi cities of zinc-Finger nucleases by in vitro selection. Nat Methods. 2011;8:765-70.
164. Li L, Piatek MJ, Atef A, Piatek A, Wibowo A, Fang X, et al. Rapid and highly Efficient construction of TALE-Based transcriptional regulators and nucleases for genome modifi -Cation. Plant Mol Biol. 78:407-16.
165. Mussolino C, Morbitzer R, Lutge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011;39:9283-93.
166. Arnould S, Chames P, Perez C, Lacroix E, Duclert A, Epinat JC, et al. Engineering of large numbers of highly specifi c homing endonucleases that induce recombination on novel DNA targets. J Mol Biol. 2006;355:443-58.
167. Stoddard BL. Homing endonucleases: From microbial genetic invaders to reagents for targeted DNA modifi cation. Structure. 2011;19:7-15.
168. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6: 1130-46.
169. Ehsani A, Saetrom P, Zhang J, Alluin J, Li H, Snove O Jr, et al. Rational design of micro-RNA-Like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. Mol Ther. 2010;18:796-802.
170. C hattopadhyay S, Ely A, Bloom K, Weinberg MS, Arbuthnot P. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009;389:484-9.
171. Shrivastava N, Srivastava A. RNA interference: An emerging generation of biologicals. Biotechnol J. 2008;3:339-53.
172. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005;12:217-27.
173. Brown BD, Naldini L. Exploiting and antagonizing micro-RNA regulation for therapeutic and experimental applications. Nat Rev Genet. 2009;10:578-85.
174. Zhong YQ, Xia ZS, Fu YR, Zhu ZH. Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J Dig Dis. 2010;11:176-84.
175. Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-Promoted anti-HIV RNAs. Mol Ther. 2003;8:196-206.
176. Anderson J, Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 2007;14:1287-97.
177. Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 2008;28:2259-63.
178. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol. 2007;25:1457-67.
179. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-Cell transplantation for leukaemia (the TK007 trial): A non-Randomised phase I-II study. Lancet Oncol. 2009;10: 489-500.
180. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673-83.
181. Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, et al. IL-7 and IL-15 allow the generation of suicide gene-Modified alloreactive self-Renewing central memory human T lymphocytes. Blood. 2009;113:1006-15.
182. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-Compliant non-Viral method. Cancer Gene Ther. 2010;17:147-54.
183. Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol. 2008;423:139-53.
184. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674-83.
185. McLachlan G, Davidson H, Holder E, Davies LA, Pringle IA, Sumner-Jones SG, et al. Pre-Clinical evaluation of three non-Viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther. 2011;18:996-1005.
186. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: An emerging field. Toxicol Pathol. 2008;36:21-9.
187. Hosseinkhani H, Tabata Y. Self assembly of DNA nanoparticles with polycations for the delivery of genetic materials into cells. J Nanosci Nanotechnol. 2006;6:2320-8.
188. Orlando SJ, Santiago Y, DeKelver RC, Freyvert Y, Boydston EA, Moehle EA, et al. Zinc-Finger nuclease-Driven targeted integration into mammalian genomes using donors with limited chromosomal homology. Nucleic Acids Res. 2010;38:e152.
189. Benabdallah BF, Allard E, Yao S, Friedman G, Gregory PD, Eliopoulos N, et al. Targeted gene addition to human mesenchymal stromal cells as a cell-Based plasma-Soluble protein delivery platform. Cytotherapy. 2010;12:394-9.
190. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol. 2011;29:73-8.
191. Gersbach CA, Gaj T, Gordley RM, Mercer AC, Barbas CF 3rd. Targeted plasmid integration into the human genome by an engineered zinc-Finger recombinase. Nucleic Acids Res. 2011;39:7868-78.
192. Russom D, Ahmed A, Gonzalez N, Alvarnas J, DiGiusto D. Implementation of a confi gurable laboratory information management system for use in cellular process development and manufacturing. Cytotherapy. 2012;14:114-21.
193. Trounson A, Dewitt ND. Stem cell biology: Towards the reality of cell therapeutics. Nature Cell Biology. 2012; 14:331.
194. Trounson A, DeWitt ND, Feigal EG. The alpha stem cell clinic: A model for evaluating and delivering stem cell-Based therapies. Stem Cells Trans Med. 2012;1:9-14.